Menlo Park's Intersect ENT latest health/bio IPO to lower target

Nasal implant maker Intersect ENT is the latest in the health and biotech sector to lower its IPO targets, setting price targets to raise up to $74...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.